References
- 1. Burke W, Atkins D, Gwinn M, et al. Genetic test evaluation: information needs of clinicians, policy makers, and the public. Am J Epidemiol. 2002;156:311-318.
- 2. Holtzman NA, Watson MS. Promoting safe and effective genetic testing in the United States. Final report of the Task Force on Genetic Testing. J Child Fam Nurs. 1999 Sep-Oct; 2(5):388-90.
- 3. Khoury MJ, Jones K, Grosse SD. Quantifying the health benefits of genetic tests: the importance of a population perspective. Genet Med 2006;8:191-195.
- 4. Javaher P, Kaariainen H, Kristoffersson U, Nippert I, Sequeiros J, Zimmern R, Schmidtke J. EuroGentest: DNA-based testing for heritable disorders in Europe. Community Genet. 2008;11(2):75-120.
- 5. Newman NJ, Biousse V. Hereditary optic neuropathies. Eye 2004;18:1144-6010.1038/sj.eye.6701591
- 6. Kondo H, Qin M, Tahira T, Uchio E, Hayashi K. Severe form of familial exudative vitreoretinopathy caused by homozygous R417Q mutation in frizzled-4 gene. Ophthalmic Genet 2007;28: 220-3.10.1080/13816810701663543
- 7. Robitaille JM, Wallace K, Zheng B, et al. Phenotypic overlap of familial exudative vitreoretinopathy (FEVR) with persistent fetal vasculature (PFV) caused by FZD4 mutations in two distinct pedigrees. Ophthalmic Genet 2009;30:23-30.10.1080/13816810802464312
- 8. Chung DC, Traboulsi EI. Leber congenital amaurosis: Clinical correlations with genotypes, gene therapy trials update, and future directions. J AAPOS 2009;13:587-92.
- 9. Corson TW and Gallie BL. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer 46:617-634
- 10. Sharif W and Sharif Z. Leber’s congenital amaurosis and the role of gene therapy in congenital retinal disorders Int J Ophthalmol. 2017; 10(3): 480-484.
- 11. Maclachlan TK, Lukason M, Collins M, Munger R, Isenberger E, Rogers C, Malatos S, Dufresne E, Morris J, Calcedo R, Veres G, Scaria A, Andrews L, Wadsworth S. Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration. Mol Ther. 2011;19(2):326-334.
- 12. Stone EM, Aldave AJ, Drack AV et al. Recommendations for genetic testing of inherited eye diseases: report of the American Academy of Ophthalmology task force on genetic testing. Ophthalmology 2012: 119 (11): 2408-2410.
- 13. Borry P and Howard HC. Personal genome testing: do you know what you are buying? Am J Bioeth. 2009;9(6-7):11-3.
- 14. Parke DW The American Academy of Ophthalmology and the Formation of the American Board of Ophthalmology. Ophthalmology. 2016 Sep;123(9 Suppl):S12-4.
- 15. Morad Y, Sutherland J, DaSilva L, et al. The Ocular Genetics Program: multidisciplinary care of patients with ocular genetic eye disease. Can J Ophthalmol 2007; 42:734-738.10.3129/i07-144
- 16. Gabriel LAR and Traboulsi EI. Genetic Diagnostic Methods for Inherited Eye Diseases. Middle East Afr J Ophthalmol. 2011; 18(1): 24-29.
- 17. Xuan J, Yu Y, Qing T, Guo L, Shi L. Next-generation sequencing in the clinic: promises and challenges. Cancer Lett 2013; 340: 284-295.
- 18. Grody WW, Thompson BH, Gregg AR, Bean LH, Monaghan KG, Schneider A, Lebo RV. ACMG position statement on prenatal/ preconception expanded carrier screening. Genet Med. 2013; 15(6):482-48310.1038/gim.2013.47
- 19. Consugar MB, Navarro-Gomez D, Place E, Bujakowska KM, Sousa ME, Fonseca-Kelly ZD, Taub DG, Janessian M, Wang DY, Au ED, Sims KB, Sweetser DA, Fulton AB, Liu Q, Wiggs JL, Gai X, Pierce EA. Panel-based genetic diagnostic testing for inherited eye diseases is highly accurate and reproducible and more sensitive for variant detection than exome sequencing. Genet Med. 2015; 17(4): 253-261.
- 20. Gillespie RL, O’Sullivan J, Ashworth J et al: Personalized diagnosis and management of congenital cataract by next-generation sequencing. Ophthalmology 2014; 121: 2124-2137 e2121-2122.
- 21. Sullivan LS, Bowne SJ, Seaman CR, et al. Genomic rearrangements of the PRPF31 gene account for 2.5% of autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci 2006;47:4579-4588.
- 22. Anasagasti A, Irigoyen C, Barandika O, López de Munain A, Ruiz-Ederra J. Current mutation discovery approaches in Retinitis Pigmentosa. Vision Res 2012;75:117-129.
- 23. Lee H, Deignan JL, Dorrani N, et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA 2014;312:1880-1887.
- 24. O’Sullivan J, Mullaney BG, Bhaskar SS et al. A paradigm shift in the delivery of services for diagnosis of inherited retinal disease. J Med Genet 2012: 49: 322-326.
- 25. Harvey A, Brand A, Holgate ST et al. The future of technologies for personalised medicine. N Biotechnol 2012: 29: 625-633.
- 26. Chair SR, Aziz N, Bale S, Bick D, Das S, Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17(5): 405-424.
- 27. Fan BJ, Wiggs JL. Glaucoma: genes, phenotypes, and new directions for therapy. Journal Clinical Investigation. 2010;120:3064-72.
- 28. Wiggs JL, Howell GR, Linkroum K, Abdrabou W, Hodges E, Braine CE, Pasquale LR, Hannon GJ, Haines JL, John SWM. Variations in COL15A1 and COL18A1 influence age of onset of primary open angle glaucoma. Clin Genet. 2013; 84(2):167-74.10.1111/cge.12176
- 29. Boye SE, Boye SL, Lewin AS, Hauswirth WW. A comprehensive review of retinal gene therapy. Mol Ther 2013: 21 (3): 509-519.10.1038/mt.2012.280
- 30. Blain D, Goetz KE, Ayyagari R, Tumminiac SJ. eyeGENE®: a vision community resource facilitating patient care and paving the path for research through molecular diagnostic testing. Clin Genet. 2013 Aug; 84(2): 10.1111/cge.12193.